Condition
Partial Lipodystrophy
Total Trials
5
Recruiting
3
Active
4
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (2)
P 3 (1)
P 4 (1)
Trial Status
Recruiting3
Completed1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02325674Recruiting
MEASuRE: Metreleptin Effectiveness And Safety Registry
NCT05164341Phase 3Active Not RecruitingPrimary
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
NCT05470504Phase 2Recruiting
Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
NCT06484868Phase 4RecruitingPrimary
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
NCT00896298Phase 2Completed
Trial of Leptin Replacement Therapy in Patients With Lipodystrophy
Showing all 5 trials